Table 3.

Secondary study end-points

IL-1RaPlaceboP
Hepatic veno-occlusive disease (%) 29 27  .74 
Median time to neutrophil recovery (d) 24 23.5 .25  
100-day survival (all patients) 74% 76% > .99 
 (95% CI, 66%-83%) (95% CI, 66%-85%)  
IL-1RaPlaceboP
Hepatic veno-occlusive disease (%) 29 27  .74 
Median time to neutrophil recovery (d) 24 23.5 .25  
100-day survival (all patients) 74% 76% > .99 
 (95% CI, 66%-83%) (95% CI, 66%-85%)  
View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal